Clinical Trial Update: A Clinical Study of TJ004309 With Atezolizumab (TECENTRIQ®) in Patients With Ovarian Cancer and Selected Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial of TJ004309 in combination with atezolizumab (TECENTRIQ) for ovarian cancer and selected solid tumors has completed enrollment with resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastrointestinal Cancer
• Head and Neck Cancer
• Non-small Cell Lung Cancer
• Ovarian Cancer
• Ovarian Carcinoma
• Triple-negative Breast Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• TJ004309

Snippet

Sponsor: I-Mab Biopharma US Limited | Conditions: Ovarian Cancer, Head and Neck Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-12-16